immunocore.com (IMCR): Rasio rega marang prakiraan pendapatan

IMCR (Immunocore Holdings) - tandha merek perusahaan

Immunocore Holdings plc utilizes a unique TCR platform to combat solid tumors and ocular melanoma. The GURU.Markets terminal displays the company's expected P/S chart, where the value 3.30 represents the current metric. This British breakthrough in oncology has secured physician trust for the brand. Leadership in treating rare cancers guarantees high margins and strong pricing power.

IMCR Immunocore Holdings: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 18.11.2026

Rincian analitis perusahaan Immunocore Holdings plc (IMCR)

Ringkesan analisis perusahaan:immunocore.com IMCR
Produk sing diprodhuksi Immunocore Corp

Immunocore Holdings plc (IMCR) is transitioning to the commercial scaling stage, leveraging operating leverage to optimize research costs. The current calculated coefficient 3.30 reflects the ratio of market capitalization to projected annual revenue, measuring the premium for future growth. Investors utilize this metric to assess whether the asset is overbought relative to expected cash flows. The trend of the company's expected P/S on the GURU.Markets platform allows for the real-time assessment of shifting market sentiment.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Janux Corp JANX|RCUS - Rasio rega marang prakiraan pendapatan|ZYME (zymeworks.com) - Kapitalisasi marang prakiraan pendapatan|Tango Therapeutics Corp (TNGX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Iovance (IOVA)|Multiplikator forward rega marang pendapatan IMTX|XNCR - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan CMPX (Compass Bio)|Rasio rega marang pendapatan sing dikarepake REPL|Multiplikator Forward P/S LYEL (Lyell Immunopharma, Inc.)|Rega forward marang dodolan IPHA|Pyxis - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Compugen|IO Biotech, Inc. (IOBT) - Rasio rega marang prakiraan pendapatan|Sutro Biopharma, Inc. - Rega forward marang dodolan|INKT (minktherapeutics.com) - Multiplikator Forward P/S|Multiplikator Forward P/S werewolftx.com|Rasio rega marang prakiraan pendapatan immixbio.com (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP